Daratumumab in Monoclonal Gammopathy of Renal Significance in Finland, DAMOCLES

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517676-37-01

Acronym

MGRS 1.8

Enrollment

Registered

2025-01-29

Start date

2025-06-01

Completion date

Unknown

Last updated

2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Monoclonal Gammopathy of Renal Significance (MGRS)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Finland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026